Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | FABP4 | P15090 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4010777 | 0.86 | TSHR (0.54) | TSHRKDM4EKMT2AMEN1HPGD | |
| SCHEMBL12231091 | 0.83 | NPC1 (0.60) | TSHRKDM4EKMT2AMEN1HPGD | |
| SCHEMBL4517524 | 0.82 | TSHR (0.58) | TSHRKDM4EKMT2AMEN1HPGD | |
| SCHEMBL12231094 | 0.82 | TSHR (0.58) | TSHRKDM4EKMT2AMEN1HPGD | |
| SCHEMBL4511943 | 0.79 | MEN1 (0.67) | TSHRKDM4EKMT2AMEN1HPGD | |
| SCHEMBL20219039 | 0.77 | TSHR (0.76) | TSHRKDM4EKMT2AMEN1HPGD | |
| SCHEMBL4010775 | 0.76 | KMT2A (0.66) | TSHRKDM4EKMT2AMEN1FABP4 | |
| SCHEMBL31023418 | 0.75 | TSHR (0.73) | TSHRKDM4EKMT2AMEN1HPGD | |
| SCHEMBL4002460 | 0.75 | TSHR (0.73) | TSHRKDM4EKMT2AMEN1HPGD | |
| SCHEMBL10032004 | 0.74 | TSHR (0.71) | TSHRKDM4EKMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069286-B1 | INHIBITORS FOR GLYT-1 | HOFFMANN LA ROCHE (CH) | 2012-09-19 | — | — | EP | claimed |
| US-7589089-B2 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. (US) | 2009-09-15 | — | — | US | claimed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | claimed |
| EP-2069286-B1 | INHIBITORS FOR GLYT-1 | HOFFMANN LA ROCHE (CH) | 2012-09-19 | — | — | EP | disclosed |
| US-7589089-B2 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058331-A1 | Inhibitors for GlyT-1 | GLRA1, SLC1A2, AGXT | TSHR 1554/4885KDM4E 1690/4885KMT2A 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.